abstract |
The present invention relates to the use of an IgG2 anti-CD25 antibody, which does not inhibit IL-2-CD25 interaction, with improved binding to activate Fcgamma Rs resulting in efficient depletion of Treg infiltrating cells. tumors and better control of established tumors. The antibody can be used in the treatment of cancer, for example in the treatment of solid tumors and in hematological cancers. |